<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>MP</title>
  <meta name="description" content="This is a minimal example of using the bookdown package to write a book. The output format for this example is bookdown::gitbook.">
  <meta name="generator" content="bookdown 0.7.8 and GitBook 2.6.7">

  <meta property="og:title" content="MP" />
  <meta property="og:type" content="book" />
  
  
  <meta property="og:description" content="This is a minimal example of using the bookdown package to write a book. The output format for this example is bookdown::gitbook." />
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="MP" />
  
  <meta name="twitter:description" content="This is a minimal example of using the bookdown package to write a book. The output format for this example is bookdown::gitbook." />
  

<meta name="author" content="pqi">



  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="sbrt.html">
<link rel="next" href="implants.html">
<script src="libs/jquery-2.2.3/jquery.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="style.css" type="text/css" />
<link rel="stylesheet" href="font-awesome.min.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">A Minimal Book Example</a></li>

<li class="divider"></li>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Welcome</a></li>
<li class="chapter" data-level="1" data-path="intro.html"><a href="intro.html"><i class="fa fa-check"></i><b>1</b> Introduction</a><ul>
<li class="chapter" data-level="1.1" data-path="intro.html"><a href="intro.html#constants"><i class="fa fa-check"></i><b>1.1</b> Physics constant</a></li>
<li class="chapter" data-level="1.2" data-path="intro.html"><a href="intro.html#atomic-rep"><i class="fa fa-check"></i><b>1.2</b> Atomic Representation</a></li>
<li class="chapter" data-level="1.3" data-path="intro.html"><a href="intro.html#classification-of-atoms"><i class="fa fa-check"></i><b>1.3</b> Classification of Atoms</a></li>
<li class="chapter" data-level="1.4" data-path="intro.html"><a href="intro.html#stability"><i class="fa fa-check"></i><b>1.4</b> Stability</a></li>
<li class="chapter" data-level="1.5" data-path="intro.html"><a href="intro.html#mass-defect"><i class="fa fa-check"></i><b>1.5</b> Mass Defect</a></li>
<li class="chapter" data-level="1.6" data-path="intro.html"><a href="intro.html#einstein"><i class="fa fa-check"></i><b>1.6</b> High energy charged particles</a></li>
<li class="chapter" data-level="1.7" data-path="intro.html"><a href="intro.html#high-energy-photons"><i class="fa fa-check"></i><b>1.7</b> High energy photons</a></li>
<li class="chapter" data-level="1.8" data-path="intro.html"><a href="intro.html#electron-shell"><i class="fa fa-check"></i><b>1.8</b> Electron Shell</a></li>
<li class="chapter" data-level="1.9" data-path="intro.html"><a href="intro.html#solutions"><i class="fa fa-check"></i><b>1.9</b> Solutions</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="nut.html"><a href="nut.html"><i class="fa fa-check"></i><b>2</b> Nuclear Transformation</a><ul>
<li class="chapter" data-level="2.1" data-path="nut.html"><a href="nut.html#decays"><i class="fa fa-check"></i><b>2.1</b> Decay (disintegration)</a></li>
<li class="chapter" data-level="2.2" data-path="nut.html"><a href="nut.html#activity"><i class="fa fa-check"></i><b>2.2</b> Activity</a></li>
<li class="chapter" data-level="2.3" data-path="nut.html"><a href="nut.html#decay-unit"><i class="fa fa-check"></i><b>2.3</b> Unit</a></li>
<li class="chapter" data-level="2.4" data-path="nut.html"><a href="nut.html#nucl-solution"><i class="fa fa-check"></i><b>2.4</b> Solutions</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="prox.html"><a href="prox.html"><i class="fa fa-check"></i><b>3</b> Production of X-rays</a><ul>
<li class="chapter" data-level="3.1" data-path="prox.html"><a href="prox.html#history"><i class="fa fa-check"></i><b>3.1</b> History</a><ul>
<li class="chapter" data-level="3.1.1" data-path="prox.html"><a href="prox.html#conventional-x-ray-tubes"><i class="fa fa-check"></i><b>3.1.1</b> Conventional x-ray tubes</a></li>
</ul></li>
<li class="chapter" data-level="3.2" data-path="prox.html"><a href="prox.html#x-ray-spectra"><i class="fa fa-check"></i><b>3.2</b> X-ray spectra</a></li>
</ul></li>
<li class="chapter" data-level="4" data-path="gene.html"><a href="gene.html"><i class="fa fa-check"></i><b>4</b> Clinical Treatment Generators</a><ul>
<li class="chapter" data-level="4.1" data-path="gene.html"><a href="gene.html#history-1"><i class="fa fa-check"></i><b>4.1</b> History</a></li>
<li class="chapter" data-level="4.2" data-path="gene.html"><a href="gene.html#waveguide"><i class="fa fa-check"></i><b>4.2</b> Waveguide</a></li>
<li class="chapter" data-level="4.3" data-path="gene.html"><a href="gene.html#microwave-amplifier"><i class="fa fa-check"></i><b>4.3</b> Microwave amplifier</a></li>
<li class="chapter" data-level="4.4" data-path="gene.html"><a href="gene.html#microwave-frequency"><i class="fa fa-check"></i><b>4.4</b> Microwave frequency</a></li>
<li class="chapter" data-level="4.5" data-path="gene.html"><a href="gene.html#penumbra"><i class="fa fa-check"></i><b>4.5</b> Penumbra</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="inter.html"><a href="inter.html"><i class="fa fa-check"></i><b>5</b> Interaction</a><ul>
<li class="chapter" data-level="5.1" data-path="inter.html"><a href="inter.html#photo-el"><i class="fa fa-check"></i><b>5.1</b> Photoelectric interactions</a></li>
<li class="chapter" data-level="5.2" data-path="inter.html"><a href="inter.html#compton"><i class="fa fa-check"></i><b>5.2</b> Compton interactions</a></li>
<li class="chapter" data-level="5.3" data-path="inter.html"><a href="inter.html#pair"><i class="fa fa-check"></i><b>5.3</b> Pair production</a></li>
<li class="chapter" data-level="5.4" data-path="inter.html"><a href="inter.html#compton-interactions"><i class="fa fa-check"></i><b>5.4</b> Compton interactions</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="measurement.html"><a href="measurement.html"><i class="fa fa-check"></i><b>6</b> Measurement of Ionizing Radiation</a><ul>
<li class="chapter" data-level="6.1" data-path="measurement.html"><a href="measurement.html#collection-volume"><i class="fa fa-check"></i><b>6.1</b> Collection volume</a></li>
<li class="chapter" data-level="6.2" data-path="measurement.html"><a href="measurement.html#signal-of-an-ion-chamber"><i class="fa fa-check"></i><b>6.2</b> Signal of an ion chamber</a></li>
<li class="chapter" data-level="6.3" data-path="measurement.html"><a href="measurement.html#temperature-and-pressure-correction"><i class="fa fa-check"></i><b>6.3</b> Temperature and pressure correction</a></li>
<li class="chapter" data-level="6.4" data-path="measurement.html"><a href="measurement.html#guard-electrode"><i class="fa fa-check"></i><b>6.4</b> Guard electrode</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="quality.html"><a href="quality.html"><i class="fa fa-check"></i><b>7</b> Quality of X-rays</a></li>
<li class="chapter" data-level="8" data-path="dose.html"><a href="dose.html"><i class="fa fa-check"></i><b>8</b> Absorbed Dose</a><ul>
<li class="chapter" data-level="8.1" data-path="dose.html"><a href="dose.html#optical-density"><i class="fa fa-check"></i><b>8.1</b> Optical density</a></li>
<li class="chapter" data-level="8.2" data-path="dose.html"><a href="dose.html#q9-od"><i class="fa fa-check"></i><b>8.2</b> Q9 OD</a></li>
</ul></li>
<li class="chapter" data-level="9" data-path="distribution.html"><a href="distribution.html"><i class="fa fa-check"></i><b>9</b> Dose Distributions</a><ul>
<li class="chapter" data-level="9.1" data-path="distribution.html"><a href="distribution.html#tar"><i class="fa fa-check"></i><b>9.1</b> TAR</a></li>
</ul></li>
<li class="chapter" data-level="10" data-path="dosecalc.html"><a href="dosecalc.html"><i class="fa fa-check"></i><b>10</b> Dose calcuation</a></li>
<li class="chapter" data-level="11" data-path="planning1.html"><a href="planning1.html"><i class="fa fa-check"></i><b>11</b> Treatment Planning I: Isodose Distribution and Plan Evaluation</a><ul>
<li class="chapter" data-level="11.1" data-path="planning1.html"><a href="planning1.html#penumbra-1"><i class="fa fa-check"></i><b>11.1</b> Penumbra</a></li>
<li class="chapter" data-level="11.2" data-path="planning1.html"><a href="planning1.html#wedges"><i class="fa fa-check"></i><b>11.2</b> Wedges</a></li>
</ul></li>
<li class="chapter" data-level="12" data-path="planning2.html"><a href="planning2.html"><i class="fa fa-check"></i><b>12</b> Treatment Planning II: Patient Data, Corrections, and Setup</a><ul>
<li class="chapter" data-level="12.1" data-path="planning2.html"><a href="planning2.html#inhomogeneity"><i class="fa fa-check"></i><b>12.1</b> Inhomogeneity</a></li>
<li class="chapter" data-level="12.2" data-path="planning2.html"><a href="planning2.html#range"><i class="fa fa-check"></i><b>12.2</b> Range</a></li>
<li class="chapter" data-level="12.3" data-path="planning2.html"><a href="planning2.html#mri"><i class="fa fa-check"></i><b>12.3</b> MRI</a></li>
<li class="chapter" data-level="12.4" data-path="planning2.html"><a href="planning2.html#pet"><i class="fa fa-check"></i><b>12.4</b> PET</a></li>
</ul></li>
<li class="chapter" data-level="13" data-path="planning3.html"><a href="planning3.html"><i class="fa fa-check"></i><b>13</b> Treatment Planning III: Field shaping, skin dose, and field separation</a><ul>
<li class="chapter" data-level="13.1" data-path="planning3.html"><a href="planning3.html#hvl"><i class="fa fa-check"></i><b>13.1</b> HVL</a></li>
<li class="chapter" data-level="13.2" data-path="planning3.html"><a href="planning3.html#q2-3-4-and-7-range"><i class="fa fa-check"></i><b>13.2</b> Q2, 3, 4, and 7 Range</a></li>
</ul></li>
<li class="chapter" data-level="14" data-path="electron.html"><a href="electron.html"><i class="fa fa-check"></i><b>14</b> Electron</a><ul>
<li class="chapter" data-level="14.1" data-path="electron.html"><a href="electron.html#history-2"><i class="fa fa-check"></i><b>14.1</b> History</a></li>
<li class="chapter" data-level="14.2" data-path="electron.html"><a href="electron.html#treatment-sites"><i class="fa fa-check"></i><b>14.2</b> Treatment Sites</a></li>
<li class="chapter" data-level="14.3" data-path="electron.html"><a href="electron.html#e-interactions"><i class="fa fa-check"></i><b>14.3</b> Interactions</a></li>
<li class="chapter" data-level="14.4" data-path="electron.html"><a href="electron.html#e-delivery"><i class="fa fa-check"></i><b>14.4</b> Delivery</a></li>
<li class="chapter" data-level="14.5" data-path="electron.html"><a href="electron.html#beam-quality"><i class="fa fa-check"></i><b>14.5</b> Beam quality</a></li>
<li class="chapter" data-level="14.6" data-path="electron.html"><a href="electron.html#internal-shielding"><i class="fa fa-check"></i><b>14.6</b> Internal shielding</a></li>
<li class="chapter" data-level="14.7" data-path="electron.html"><a href="electron.html#total-skin-electron-irradiation-tsei"><i class="fa fa-check"></i><b>14.7</b> Total skin electron irradiation (TSEI)</a></li>
<li class="chapter" data-level="14.8" data-path="electron.html"><a href="electron.html#e-solu"><i class="fa fa-check"></i><b>14.8</b> Solutions</a></li>
</ul></li>
<li class="chapter" data-level="15" data-path="brachy.html"><a href="brachy.html"><i class="fa fa-check"></i><b>15</b> Brachytherapy</a><ul>
<li class="chapter" data-level="15.1" data-path="brachy.html"><a href="brachy.html#isotopes"><i class="fa fa-check"></i><b>15.1</b> Isotopes</a><ul>
<li class="chapter" data-level="15.1.1" data-path="brachy.html"><a href="brachy.html#radium-sources"><i class="fa fa-check"></i><b>15.1.1</b> Radium sources</a></li>
<li class="chapter" data-level="15.1.2" data-path="brachy.html"><a href="brachy.html#radium-substitutes"><i class="fa fa-check"></i><b>15.1.2</b> Radium substitutes</a></li>
</ul></li>
<li class="chapter" data-level="15.2" data-path="brachy.html"><a href="brachy.html#source-strength"><i class="fa fa-check"></i><b>15.2</b> Source strength</a><ul>
<li class="chapter" data-level="15.2.1" data-path="brachy.html"><a href="brachy.html#sk"><i class="fa fa-check"></i><b>15.2.1</b> Unit: Air-kerma strength <span class="math inline">\(S_k\)</span></a></li>
</ul></li>
<li class="chapter" data-level="15.3" data-path="brachy.html"><a href="brachy.html#radiation-dose-from-brachytherpay-sources"><i class="fa fa-check"></i><b>15.3</b> Radiation dose from brachytherpay sources</a><ul>
<li class="chapter" data-level="15.3.1" data-path="brachy.html"><a href="brachy.html#from-exposure-rate"><i class="fa fa-check"></i><b>15.3.1</b> From exposure rate</a></li>
<li class="chapter" data-level="15.3.2" data-path="brachy.html"><a href="brachy.html#tg43"><i class="fa fa-check"></i><b>15.3.2</b> TG-43</a></li>
</ul></li>
<li class="chapter" data-level="15.4" data-path="brachy.html"><a href="brachy.html#ldr-solutions"><i class="fa fa-check"></i><b>15.4</b> Solutions</a></li>
<li class="chapter" data-level="15.5" data-path="brachy.html"><a href="brachy.html#traceability"><i class="fa fa-check"></i><b>15.5</b> Traceability</a></li>
</ul></li>
<li class="chapter" data-level="16" data-path="protection.html"><a href="protection.html"><i class="fa fa-check"></i><b>16</b> Radiation Protection</a><ul>
<li class="chapter" data-level="16.1" data-path="protection.html"><a href="protection.html#sources-of-radiation-exposure"><i class="fa fa-check"></i><b>16.1</b> Sources of radiation exposure</a></li>
<li class="chapter" data-level="16.2" data-path="protection.html"><a href="protection.html#stochastic-and-deterministic-event"><i class="fa fa-check"></i><b>16.2</b> Stochastic and deterministic event</a></li>
<li class="chapter" data-level="16.3" data-path="protection.html"><a href="protection.html#tds-rule"><i class="fa fa-check"></i><b>16.3</b> TDS rule</a></li>
</ul></li>
<li class="chapter" data-level="17" data-path="qa.html"><a href="qa.html"><i class="fa fa-check"></i><b>17</b> QA</a></li>
<li class="chapter" data-level="18" data-path="tbi.html"><a href="tbi.html"><i class="fa fa-check"></i><b>18</b> TBI</a></li>
<li class="chapter" data-level="19" data-path="crt.html"><a href="crt.html"><i class="fa fa-check"></i><b>19</b> Three-dimensional conformal radiotherapy</a><ul>
<li class="chapter" data-level="19.1" data-path="crt.html"><a href="crt.html#icru-reference-point"><i class="fa fa-check"></i><b>19.1</b> ICRU reference point</a></li>
<li class="chapter" data-level="19.2" data-path="crt.html"><a href="crt.html#image-registration"><i class="fa fa-check"></i><b>19.2</b> Image registration</a></li>
<li class="chapter" data-level="19.3" data-path="crt.html"><a href="crt.html#image-segmentation"><i class="fa fa-check"></i><b>19.3</b> Image segmentation </a></li>
<li class="chapter" data-level="19.4" data-path="crt.html"><a href="crt.html#cumulative-dvh"><i class="fa fa-check"></i><b>19.4</b> Cumulative DVH</a></li>
<li class="chapter" data-level="19.5" data-path="crt.html"><a href="crt.html#differential-dvh"><i class="fa fa-check"></i><b>19.5</b> Differential DVH</a></li>
</ul></li>
<li class="chapter" data-level="20" data-path="imrt.html"><a href="imrt.html"><i class="fa fa-check"></i><b>20</b> IMRT</a><ul>
<li class="chapter" data-level="20.1" data-path="imrt.html"><a href="imrt.html#imrt"><i class="fa fa-check"></i><b>20.1</b> IMRT</a></li>
<li class="chapter" data-level="20.2" data-path="imrt.html"><a href="imrt.html#transmission-or-leakage"><i class="fa fa-check"></i><b>20.2</b> Transmission or leakage</a></li>
<li class="chapter" data-level="20.3" data-path="imrt.html"><a href="imrt.html#q4-mu-imrt-vs.3dcrt"><i class="fa fa-check"></i><b>20.3</b> Q4 MU: IMRT vs. 3DCRT</a></li>
<li class="chapter" data-level="20.4" data-path="imrt.html"><a href="imrt.html#q5"><i class="fa fa-check"></i><b>20.4</b> Q5</a></li>
<li class="chapter" data-level="20.5" data-path="imrt.html"><a href="imrt.html#shielding-for-imrt"><i class="fa fa-check"></i><b>20.5</b> Shielding for IMRT</a></li>
<li class="chapter" data-level="20.6" data-path="imrt.html"><a href="imrt.html#section"><i class="fa fa-check"></i><b>20.6</b> </a></li>
<li class="chapter" data-level="20.7" data-path="imrt.html"><a href="imrt.html#q8"><i class="fa fa-check"></i><b>20.7</b> Q8</a></li>
<li class="chapter" data-level="20.8" data-path="imrt.html"><a href="imrt.html#q9"><i class="fa fa-check"></i><b>20.8</b> Q9</a></li>
<li class="chapter" data-level="20.9" data-path="imrt.html"><a href="imrt.html#q10"><i class="fa fa-check"></i><b>20.9</b> Q10</a></li>
<li class="chapter" data-level="20.10" data-path="imrt.html"><a href="imrt.html#mlc-tests"><i class="fa fa-check"></i><b>20.10</b> MLC test(s)</a></li>
<li class="chapter" data-level="20.11" data-path="imrt.html"><a href="imrt.html#q12"><i class="fa fa-check"></i><b>20.11</b> Q12</a></li>
</ul></li>
<li class="chapter" data-level="21" data-path="sbrt.html"><a href="sbrt.html"><i class="fa fa-check"></i><b>21</b> SBRT</a><ul>
<li class="chapter" data-level="21.1" data-path="sbrt.html"><a href="sbrt.html#gamma-knife-perfexiontm-and-icon"><i class="fa fa-check"></i><b>21.1</b> GAMMA Knife Perfexion<sup>TM</sup> and Icon</a><ul>
<li class="chapter" data-level="21.1.1" data-path="sbrt.html"><a href="sbrt.html#qa-for-gk-perfexiontm-and-icontm"><i class="fa fa-check"></i><b>21.1.1</b> QA for GK Perfexion<sup>TM</sup> and Icon<sup>TM</sup></a></li>
<li class="chapter" data-level="21.1.2" data-path="sbrt.html"><a href="sbrt.html#prescision-and-accuracy"><i class="fa fa-check"></i><b>21.1.2</b> Prescision and accuracy</a></li>
</ul></li>
<li class="chapter" data-level="21.2" data-path="sbrt.html"><a href="sbrt.html#pdd-measurement"><i class="fa fa-check"></i><b>21.2</b> PDD measurement</a></li>
<li class="chapter" data-level="21.3" data-path="sbrt.html"><a href="sbrt.html#systematic-errors"><i class="fa fa-check"></i><b>21.3</b> Systematic Errors</a></li>
<li class="chapter" data-level="21.4" data-path="sbrt.html"><a href="sbrt.html#srs-cones"><i class="fa fa-check"></i><b>21.4</b> SRS cones</a></li>
<li class="chapter" data-level="21.5" data-path="sbrt.html"><a href="sbrt.html#the-definition-of-sbrt"><i class="fa fa-check"></i><b>21.5</b> The definition of SBRT</a></li>
<li class="chapter" data-level="21.6" data-path="sbrt.html"><a href="sbrt.html#diesease-sites-treatment-with-srs"><i class="fa fa-check"></i><b>21.6</b> Diesease sites treatment with SRS</a></li>
<li class="chapter" data-level="21.7" data-path="sbrt.html"><a href="sbrt.html#dose-fall-off"><i class="fa fa-check"></i><b>21.7</b> Dose fall-off</a></li>
<li class="chapter" data-level="21.8" data-path="sbrt.html"><a href="sbrt.html#dose-fall-off-continued"><i class="fa fa-check"></i><b>21.8</b> Dose fall-off continued</a></li>
<li class="chapter" data-level="21.9" data-path="sbrt.html"><a href="sbrt.html#small-field-measurements"><i class="fa fa-check"></i><b>21.9</b> Small-field measurements</a></li>
<li class="chapter" data-level="21.10" data-path="sbrt.html"><a href="sbrt.html#required-measurements-for-commissioning-a-srssbrt-program"><i class="fa fa-check"></i><b>21.10</b> Required measurements for commissioning a SRS/SBRT program</a></li>
<li class="chapter" data-level="21.11" data-path="sbrt.html"><a href="sbrt.html#gamma-knife"><i class="fa fa-check"></i><b>21.11</b> Gamma Knife</a><ul>
<li class="chapter" data-level="21.11.1" data-path="sbrt.html"><a href="sbrt.html#unilateral-vestibular-schwannomas"><i class="fa fa-check"></i><b>21.11.1</b> Unilateral Vestibular Schwannomas</a></li>
<li class="chapter" data-level="21.11.2" data-path="sbrt.html"><a href="sbrt.html#menningiomas"><i class="fa fa-check"></i><b>21.11.2</b> Menningiomas</a></li>
<li class="chapter" data-level="21.11.3" data-path="sbrt.html"><a href="sbrt.html#metastases"><i class="fa fa-check"></i><b>21.11.3</b> Metastases</a></li>
<li class="chapter" data-level="21.11.4" data-path="sbrt.html"><a href="sbrt.html#avm"><i class="fa fa-check"></i><b>21.11.4</b> AVM</a></li>
<li class="chapter" data-level="21.11.5" data-path="sbrt.html"><a href="sbrt.html#uveal-melanomas"><i class="fa fa-check"></i><b>21.11.5</b> Uveal melanomas</a></li>
</ul></li>
<li class="chapter" data-level="21.12" data-path="sbrt.html"><a href="sbrt.html#others"><i class="fa fa-check"></i><b>21.12</b> Others</a></li>
</ul></li>
<li class="chapter" data-level="22" data-path="hdr.html"><a href="hdr.html"><i class="fa fa-check"></i><b>22</b> HDR</a><ul>
<li class="chapter" data-level="22.1" data-path="hdr.html"><a href="hdr.html#hdr-vs.ldr"><i class="fa fa-check"></i><b>22.1</b> HDR vs. LDR</a></li>
<li class="chapter" data-level="22.2" data-path="hdr.html"><a href="hdr.html#common-indications-in-practice"><i class="fa fa-check"></i><b>22.2</b> Common indications in practice</a></li>
<li class="chapter" data-level="22.3" data-path="hdr.html"><a href="hdr.html#hdr-qa"><i class="fa fa-check"></i><b>22.3</b> HDR-QA</a><ul>
<li class="chapter" data-level="22.3.1" data-path="hdr.html"><a href="hdr.html#daily-qa"><i class="fa fa-check"></i><b>22.3.1</b> Daily QA</a></li>
<li class="chapter" data-level="22.3.2" data-path="hdr.html"><a href="hdr.html#pretreatment-qa"><i class="fa fa-check"></i><b>22.3.2</b> Pretreatment QA</a></li>
<li class="chapter" data-level="22.3.3" data-path="hdr.html"><a href="hdr.html#source-change"><i class="fa fa-check"></i><b>22.3.3</b> Source change</a></li>
</ul></li>
<li class="chapter" data-level="22.4" data-path="hdr.html"><a href="hdr.html#medical-events"><i class="fa fa-check"></i><b>22.4</b> Medical Events</a></li>
<li class="chapter" data-level="22.5" data-path="hdr.html"><a href="hdr.html#source"><i class="fa fa-check"></i><b>22.5</b> Source</a></li>
<li class="chapter" data-level="22.6" data-path="hdr.html"><a href="hdr.html#treatment-sites-1"><i class="fa fa-check"></i><b>22.6</b> Treatment sites</a><ul>
<li class="chapter" data-level="22.6.1" data-path="hdr.html"><a href="hdr.html#endometrial-cancer"><i class="fa fa-check"></i><b>22.6.1</b> Endometrial cancer</a></li>
<li class="chapter" data-level="22.6.2" data-path="hdr.html"><a href="hdr.html#cervical"><i class="fa fa-check"></i><b>22.6.2</b> Cervical cancer</a></li>
<li class="chapter" data-level="22.6.3" data-path="hdr.html"><a href="hdr.html#breast"><i class="fa fa-check"></i><b>22.6.3</b> Breast</a></li>
<li class="chapter" data-level="22.6.4" data-path="hdr.html"><a href="hdr.html#prostate"><i class="fa fa-check"></i><b>22.6.4</b> Prostate</a></li>
</ul></li>
<li class="chapter" data-level="22.7" data-path="hdr.html"><a href="hdr.html#references"><i class="fa fa-check"></i><b>22.7</b> References</a></li>
<li class="chapter" data-level="22.8" data-path="hdr.html"><a href="hdr.html#solutions-1"><i class="fa fa-check"></i><b>22.8</b> Solutions</a></li>
</ul></li>
<li class="chapter" data-level="23" data-path="implants.html"><a href="implants.html"><i class="fa fa-check"></i><b>23</b> Implants</a><ul>
<li class="chapter" data-level="23.1" data-path="implants.html"><a href="implants.html#isotopes-1"><i class="fa fa-check"></i><b>23.1</b> Isotopes</a></li>
<li class="chapter" data-level="23.2" data-path="implants.html"><a href="implants.html#patient-release"><i class="fa fa-check"></i><b>23.2</b> Patient Release</a></li>
<li class="chapter" data-level="23.3" data-path="implants.html"><a href="implants.html#prostate-implants"><i class="fa fa-check"></i><b>23.3</b> Prostate implants</a></li>
<li class="chapter" data-level="23.4" data-path="implants.html"><a href="implants.html#y90"><i class="fa fa-check"></i><b>23.4</b> TheraSphere</a></li>
</ul></li>
<li class="chapter" data-level="24" data-path="ivbt.html"><a href="ivbt.html"><i class="fa fa-check"></i><b>24</b> Intravascular BT</a></li>
<li class="chapter" data-level="25" data-path="igrt.html"><a href="igrt.html"><i class="fa fa-check"></i><b>25</b> IGRT</a></li>
<li class="chapter" data-level="26" data-path="cyber-knife.html"><a href="cyber-knife.html"><i class="fa fa-check"></i><b>26</b> Cyber Knife</a></li>
<li class="chapter" data-level="27" data-path="proton.html"><a href="proton.html"><i class="fa fa-check"></i><b>27</b> Proton RT</a></li>
<li class="chapter" data-level="" data-path="references-1.html"><a href="references-1.html"><i class="fa fa-check"></i>References</a></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">MP</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="hdr" class="section level1">
<h1><span class="header-section-number">Chapter 22</span> HDR</h1>
<div id="hdr-vs.ldr" class="section level2">
<h2><span class="header-section-number">22.1</span> HDR vs. LDR</h2>
<ul>
<li>LDR: well-established treatment; standard doses, plan, and treatmetn time<br />
</li>
<li>HDR: Outpatient treatment, short administration time, minimal staff exposure, standard source strength, and dose optimization</li>
</ul>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/16874815">Current controversies in high-dose-rate versus low-dose-rate brachytherapy for cervical cancer</a>.<br />
<a href="https://www.aapm.org/education/vl/vl.asp?id=3911%5D">Showalter 2014 AAPM</a></p>
</div>
<div id="common-indications-in-practice" class="section level2">
<h2><span class="header-section-number">22.2</span> Common indications in practice</h2>
<ul>
<li><strong>GYN</strong> (cervical, uterine, vaginal, vulvar)</li>
<li><strong>Prostate</strong> (monotherapy or boost)</li>
<li><strong>Breast</strong> (accelerated partial breast irradiation)</li>
<li>possible <code>Sarcoma, skin, esophagus, bile duct</code></li>
</ul>
<div class="info">
<p>
<a href="http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD007563.pub2/abstract">Cochrane review</a> and its <a href="https://www.ncbi.nlm.nih.gov/m/pubmed/25300170/?i=5&amp;from=/10432431/related">update</a>: there is no difference in OS, DSS, LC, nodal occurrence, distance occurrence was found between LDR and HDR (from a meta-analysis of 4 clinical trials in <em>Cochrane database</em> with a total of 1265 patients with advanced cervical cancer), but HDR is more convenient and accurate.
</p>
</div>
<p><span class="math inline">\(\ \)</span></p>
<div class="question">
<p>
Theoretically, HDR has a lower therapeutic ratio than LDR because of the short duration of the treatments. How? - Practical ROP chapter “Intracavitary Brachytherapy”
</p>
</div>
</div>
<div id="hdr-qa" class="section level2">
<h2><span class="header-section-number">22.3</span> HDR-QA</h2>
<div id="daily-qa" class="section level3">
<h3><span class="header-section-number">22.3.1</span> Daily QA</h3>
<p>According <a href="https://www.nrc.gov/reading-rm/doc-collections/cfr/part035/part035-0643.html">10 CFR35.643</a>, the AMP needs to review the daily QA within <strong>15 days</strong>.</p>
</div>
<div id="pretreatment-qa" class="section level3">
<h3><span class="header-section-number">22.3.2</span> Pretreatment QA</h3>
<p>Based on AAPM TG-59 describs pretreatment QA for a HDR treatment.</p>
<ol style="list-style-type: decimal">
<li>Two people (therapists?) should check proper connection of catheters to the HDR unit and that the transfer tubes are free of kinks.</li>
<li>The emergency kit and source container are available.</li>
<li>Survey meter and/or GM-counter is present and operational. (The patient may have had a nuclear medicine scan prior to the treatment, causing an elevated reading. thus a <strong>pre-treatment survey</strong> is conducted though not listed in TG-59).</li>
<li>The <strong>length</strong> of transfer tube and applicator (catheters) are correct.</li>
<li>Check applicator positioning. How do physicians check this item without image verification?</li>
<li>Treatment documentation review.
<ol style="list-style-type: lower-alpha">
<li>Signed prescription and plan.</li>
<li>Second check has been performed. (use emipircal values)</li>
<li>Plan agrees with prescription.</li>
<li>Plan is consistent with previous fractions if applicable.</li>
<li>Dwell positions and times in plan agree with what is programmed on the treatment console.</li>
</ol></li>
<li>Patient identity confirmed by two methods.</li>
</ol>
<p>At current practice, a <strong>check-list</strong> is used by physicists for pretrement plan QA and a time-out is conducted prior to initiating the treatment.</p>
</div>
<div id="source-change" class="section level3">
<h3><span class="header-section-number">22.3.3</span> Source change</h3>
<p>The half-life time is about 74 days, so the old source is sawpped with a new source about every 3 months. The activity of the new source is normally about <strong>10 Ci</strong>. According to Eq. <a href="brachy.html#eq:sk">(15.1)</a> and Eq. <a href="brachy.html#eq:exposure">(15.2)</a>, it is equal to <strong>41100 U</strong> (<span class="math inline">\(S_k = 10,000\ (mCi) \times 4.69 \left(\frac{{R\cdot cm}^2}{mCi\cdot hr} \right) \times 0.876 \left(\frac{cGy}{R}\right)\)</span>). This quantity is will be verified by an autheried medical physicist using NIST tracable well chamber and electrometer, and then enterred in the treatment planning system for dose calculation.</p>
<div class="info">
<p>
Although the well chamber (and its <sup>192</sup>Ir insert) is still within 2-year calibration period, we always double check our chamber using a NIST-calibrated <sup>137</sup>Cs source provided by our RSO.
</p>
</div>
</div>
</div>
<div id="medical-events" class="section level2">
<h2><span class="header-section-number">22.4</span> Medical Events</h2>
<ul>
<li><a href="http://www.nrc.gov/reading-rm/doccollections/nuregs/brochures/br0117/">Errors on NRC website</a></li>
<li><a href="(http://chapter.aapm.org/GLC/media/2011/tollenaar.pdf)">Wisconsin</a></li>
</ul>
</div>
<div id="source" class="section level2">
<h2><span class="header-section-number">22.5</span> Source</h2>
<p>A comprehensive seed data source can be found from a <a href="http://www.physics.carleton.ca/clrp/seed_database">database</a> provided by Carleton University</p>
<p>Because [^192^Ir](<a href="https://www.estro.org/about/governance-organisation/committees-activities/tg43-ir-192-hdr" class="uri">https://www.estro.org/about/governance-organisation/committees-activities/tg43-ir-192-hdr</a>) has much higher <code>special activity</code> than most other isotopes, it is now the mostly used radio-isotope for HDR treatment. The higher the special activity means that the <sup>192</sup> can be made with small physial dimension but still provide high radioactivity.</p>
<div class="info">
<p>
The special activity (SA) is defined as the activity per mass. It depends on half lifetime and atomic number, <span class="math inline"><span class="math inline">\(SA \propto \frac{1}{T_{1/2}\cdot A}\)</span></span>. For example, <span class="math inline"><span class="math inline">\(\frac{SA_{Co}}{SA_{Ir}} = \frac{74\ days \times 192}{5\ years \times 60} \approx 0.13\)</span></span>. Wait a second, how about SA of <sup>125</sup>I? Although <sup>125</sup>I can have higher SA than <sup>192</sup>Ir, the energy of <sup>125</sup>I is just too low for enough tissue penetration.
</p>
</div>
</div>
<div id="treatment-sites-1" class="section level2">
<h2><span class="header-section-number">22.6</span> Treatment sites</h2>
<div id="endometrial-cancer" class="section level3">
<h3><span class="header-section-number">22.6.1</span> Endometrial cancer</h3>
<p><a href="https://www.sciencedirect.com/science/article/pii/S1538472111003874?via%3Dihub">American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy</a></p>
<ul>
<li>Dose fractionation: 7Gy <span class="math inline">\(\times\)</span> 3 prescribed to 0.5 cm is a common fractionation scheme with active length of 5 cm (<span class="math inline">\(\color{Purple} {\text{Are we treating vaginal cuff or the whole vigina?}}\)</span>)</li>
<li>the standard applicator is a segmented cylinder with one central catheter; the <strong>largest diameter</strong> cylinder that patient can tolerate is used to minimize the air gap between cylinder and vagina and to avoid rapid dose fall-off.</li>
</ul>
</div>
<div id="cervical" class="section level3">
<h3><span class="header-section-number">22.6.2</span> Cervical cancer</h3>
<p><a href="">American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: General principles</a></p>
<p><a href="https://www.sciencedirect.com/science/article/pii/S1538472111003515">American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy</a></p>
<p>Cervical cancer is mostly treated with HDR brachytherapy. </p>
<ul>
<li>1903 Stockholm and Paris </li>
<li>1938 Manchester – point A</li>
<li>1953 Point A revision </li>
<li>1985 ICRU 38</li>
<li>1987 more point A updates</li>
<li>2000 GEC-ESTRO
<ul>
<li>D90, D100 for dose prescription</li>
<li>D2cc bladder, rectum, and sigmoid</li>
</ul></li>
<li>2004 GTV and CTV delineation (MRI)</li>
<li>2005 GEC-ESTRO recommendation for IGRT brachytherapy</li>
</ul>
<blockquote>
<p>Improvement occurred only in tumours &gt;5 cm: OS 28% versus 58% (p = 0.003) - R. Potter (2007) in “Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer”.</p>
</blockquote>
<p><strong>GEC-ESTRO target volumes</strong><a href="#fn17" class="footnoteRef" id="fnref17"><sup>17</sup></a></p>
<ul>
<li><code>Gross tumor volume (diagnosis)</code> (GTV<sub>D</sub>)
<ul>
<li><strong>macroscopic</strong> tumor extension at diagnosis</li>
<li>detected by clinical examination and as visualized on MRI (high signal intensity mass(es) at <em>fast spine echo</em> (FSE) sequences T2 in cervix/corpus, parametria, vagina, bladder, and rectum)</li>
</ul></li>
<li><code>Gross tumor volume (brachy)</code> (GTV<sub>B1</sub>, GTV<sub>B2</sub>, …)
<ul>
<li><strong>macroscopic</strong> tumor volume at time of brachy</li>
<li>detected by clinical examination and as visualized on MRI</li>
</ul></li>
<li><code>High risk CTV</code> (HR CTV<sub>B1</sub>, HR CTV<sub>B2</sub>, …)
<ul>
<li>includes GTV<sub>Bx</sub> and the whole cervix or MRI grey zones?</li>
<li>represent <strong>macroscopic</strong> tumor load</li>
</ul></li>
<li><code>Intermediate risk CTV</code> (IR CTV<sub>B1</sub>, IR CTV<sub>B2</sub>, …)
<ul>
<li>areas with a significant <strong>microscopic disease</strong></li>
<li>IR CTV = HR CTV + 5-15 mm margin for limited diseases</li>
<li>based on GTV<sub>D</sub> for extensive disease</li>
</ul></li>
</ul>
<p><strong>Applicator imaging</strong></p>
<div class="idea">
<p>
Availability of commercial dummy sources for MRI is limited.
</p>
</div>
<p>Based on GEC-ESTRO recommendations<a href="#fn18" class="footnoteRef" id="fnref18"><sup>18</sup></a>, the choice of MR sequence is essential for optimal visualisation of the applicator. There are difference between plastic and titanium applicators<a href="#fn19" class="footnoteRef" id="fnref19"><sup>19</sup></a></p>
<ul>
<li>Plastic has weak signal on T2; use of markers</li>
<li>Titanium has susceptibility artifact, and thus more distortions for higher magnetic strength; worse on T2; T1 is more suitable (?)</li>
<li>To understand artifacts (Why Titanium is MR compatible? - applicator induced <strong>susceptibility artifacts</strong>.)</li>
</ul>
<div class="warning">
<p>
If an applicator has been shown to be MR conditional for a 1.5T MRI, then it does <strong>not</strong> mean that it can be safely used in a 3T system without the need for further testing. CT still provides best imaging for applicator in terms of spatial accuracy (1 mm on CT vs. 1-2 mm on MRI for the localization of first dwell position) and artifacts.
</p>
</div>
<p><strong>Prescription Dose</strong></p>
<ul>
<li>HDR prescription: 5.5 Gy <span class="math inline">\(\times\)</span> 5, 6 Gy <span class="math inline">\(\times\)</span> 5, or 7 Gy <span class="math inline">\(\times\)</span> 4; once a week</li>
<li>HR CTV: total dose &gt; 85 Gy <strong>Can we go higher? or fewer fractions</strong></li>
<li>IR CTV: 60 Gy</li>
</ul>
</div>
<div id="breast" class="section level3">
<h3><span class="header-section-number">22.6.3</span> Breast</h3>
<p>ABS acceptability criteria for APBI</p>
<ul>
<li>Age: <span class="math inline">\(\ge\)</span> 50 year old</li>
<li>Size: <span class="math inline">\(\le\)</span> 3 cm</li>
<li>Histology: All invasive subtypes and DCIS</li>
<li>Estrogen receptor: +/-</li>
<li>Surgical margin: -</li>
<li>Lymphovasucular space invasion: not present</li>
<li>Nodal status: -</li>
</ul>
<p>Treatment planning</p>
<ul>
<li>34 Gy in 10 fractions twice daily</li>
<li>PTV<sub>Eval</sub> + D90% <span class="math inline">\(ge\)</span> 90% + V150 &lt; 50 cm<sup>3</sup> + V200 &lt; 10 cm<sup>3</sup> + Skin dose &lt; 145% of prescription</li>
</ul>
<p>They are slightly different from ASTRO Consensus Statement 2009.</p>
</div>
<div id="prostate" class="section level3">
<h3><span class="header-section-number">22.6.4</span> Prostate</h3>
<p><a href="https://www.sciencedirect.com/science/article/pii/S1538472111004004">American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy</a></p>
<p>Monotherapy: 13.5 Gy <span class="math inline">\(\times\)</span> 2 fractions (NCCN)</p>
</div>
</div>
<div id="references" class="section level2">
<h2><span class="header-section-number">22.7</span> References</h2>
<ul>
<li><a href="https://www.aapm.org/pubs/reports/rpt_41.pdf">TG-41 (1993)</a> Remote Afterloading Technology.</li>
<li><a href="https://www.aapm.org/pubs/reports/detail.asp?docid=50">TG-43 (1995)</a> Dosimetry of Interstitial Brachytherapy Sources.</li>
<li>TG-43U (2004) A revised AAPM protocol for brachytherapy dose calculations.</li>
<li><a href="https://www.aapm.org/pubs/reports/detail.asp?docid=58#">TG-56 (1997)</a> Code of practice for brachytherapy physics.</li>
<li><a href="https://pdfs.semanticscholar.org/5a32/c14e0720d3e5af0747e5a191845683b3feca.pdf">TG-59 (1998)</a> High dose-rate brachytherapy treatment delivery.</li>
<li><a href="https://www.aapm.org/pubs/reports/detail.asp?docid=167">AAPM UN-25 (2017)</a> Supplement 2 for the 2004 update of the AAPM Task Group No. 43 Report: Joint recommendations by the AAPM and GEC-ESTRO.</li>
<li>ABS guideline: <a href="https://www.americanbrachytherapy.org/guidelines/cervical_cancer_taskgroup.pdf" class="uri">https://www.americanbrachytherapy.org/guidelines/cervical_cancer_taskgroup.pdf</a>.</li>
</ul>
</div>
<div id="solutions-1" class="section level2">
<h2><span class="header-section-number">22.8</span> Solutions</h2>
<p><strong>Q1 Dose rate</strong> c)<br />
<strong>Q2</strong> a)<br />
<strong>Q3 TG43U </strong> d)</p>
<p>Using Eq. @ref(eq.tg43) or TG-43U1 2D Brachytherapy dosimetry formalism, <span class="math display">\[
\begin{aligned}
   \dot D(r, \theta) &amp;= \Lambda\cdot S_k \frac{G_L(r, \theta)}{G_L(r=1cm,\theta=90^o)} \cdot g_L(r, \theta)\cdot F(r,\theta)\\
   &amp;=1.12\ cGy/(h\cdot U)\cdot4.11\times10^4\text{U}\cdot1.023\cdot1\\
   &amp;=\boxed{13.1\ cGy/s}
\end{aligned}
\]</span></p>
<p><strong>Q4 Afterloader QA</strong> a)<br />
<strong>Q5 Shiedling</strong> b)<br />
<strong>Q6 Impact of decay on treatment timee</strong></p>
<p>The half-life time of Ir-192 is about 74 days, so activity after 90 days (Eq. (<a href="nut.html#eq:decay2">(2.2)</a>)) is <span class="math display">\[ A_2 = A_02^{-t/T_{1/2}}=A_02^{-90/74}=0.43A_1 \]</span> To maintain the prescribed dose (<span class="math inline">\(\dot D_1 \Delta t_1 = \dot D_2 \Delta t_2\)</span> and <span class="math inline">\(A \propto \dot D\)</span>, the dwell time <span class="math inline">\(\Delta t_2\)</span> will be <span class="math display">\[ {\Delta t_2 = \frac{\dot D_1}{\dot D_2} \Delta t_1 = \frac{\dot A_1}{\dot A_2} \Delta t_1 = \frac{1}{0.43}\times 16 \text{ min} \ \times 80\% = \boxed{29.7 \text{ min}}} \]</span> The total treatment time will be <span class="math inline">\(29.7 + 16\times20\%=\boxed{33\ \text{minutes}}\)</span>.</p>
<p><strong>Q7</strong> c)<br />
<strong>Q8</strong> c)<br />
<strong>Q9</strong> b) <strong>Q10</strong> a) but esophagus cancer is also treated with HDR but with less indication`<br />
<strong>Q11</strong> b)<br />
<strong>Q12</strong> d)</p>
<p>Workflow efficiency on day of initial treatment can be improved by completing select tasks prior to day of implantation. <em>True</em>. False.</p>
<p>Reference: Damato AL, Lee LJ, Bhagwat MS, et al. Redesign of process map to increase efficiency: Reducing procedure time in cervical cancer brachytherapy. Brachytherapy. 2015;14:471–480.</p>
<p>Which statement best describes the implementation of graphic optimization? Optimizes to user-defined dose points. Optimizes to the source dwell positions themselves as dose points. Optimizes based on prescribed dose-volume constraints. <em>O_ptimizes by the user manually adjusting isodose lines on screen</em>.</p>
<p>Reference: Dose Optimization in Gynecological 3D Image Based Interstitial Brachytherapy using Martinez Universal Perineal Interstitial Template (MUPIT) -An Institutional Experience. J Med Phys (2014) 39 (3): 197-202.</p>
<p>Reference: Kim et al., “Evaluation of artifacts and distortions of titanium applicators on 3.0-Tesla MRI: Feasibility of titanium applicators in MRI-guided brachytherapy for gynecological cancer,” Int J Radiation Oncology, 80 (3), 947-55 (2011).</p>

</div>
</div>
<div class="footnotes">
<hr />
<ol start="17">
<li id="fn17"><p>Schwarz 2015 AAPM Spring Clinical Meeting “Defining Targets for Brachytherapy” <a href="https://www.aapm.org/education/vl/vl.asp?id=4077" class="uri">https://www.aapm.org/education/vl/vl.asp?id=4077</a><a href="hdr.html#fnref17">↩</a></p></li>
<li id="fn18"><p><a href="https://www.sciencedirect.com/science/article/pii/S0167814010003683">Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group: Considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy</a><a href="hdr.html#fnref18">↩</a></p></li>
<li id="fn19"><p>Haack et al 2009 Applicator reconstruction in MRI 3D image-based dose planning of brachytherapy for cervical cancer. <a href="https://doi.org/10.1016/j.radonc.2008.09.002" class="uri">https://doi.org/10.1016/j.radonc.2008.09.002</a><a href="hdr.html#fnref19">↩</a></p></li>
</ol>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="sbrt.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="implants.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"google": false,
"linkedin": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"download": ["MP.pdf", "MP.epub"],
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "";
    if (src === "" || src === "true") src = "https://cdn.bootcss.com/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:" && /^https?:/.test(src))
      src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
